Autologous bone marrow transplantation with immunotoxin-purged marrow for advanced multiple myeloma

M. Gobbi, M. Cavo, P. L. Tazzari, A. Dinota, C. Tassi, A. Bontadin i, L. Albertazzi, C. Miggiano, S. Rizzi, G. Rosti, A. Bolognesi, F. Stirpe, S. Tura

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

A system to purge the bone marrow of myeloma cells has been developed in our laboratories with the aim of treating with myeloablative radiochemotherapy patients suffering from advanced multiple myeloma. This system is based on the ex vivo incubation of the marrow with an immunotoxin composed of the 8A monoclonal antibody - that recognizes plasma cells and B-cell precursors - and the ribosome-inactivating protein momordin. 8 patients have so far been treated. 4 are surviving from 4 to 18 months after ABMT, whereas 4 died after 1 to 6 months, 2 from infections, 1 from relapsing disease and 1 from veno-occlusive disease. A marked tumour reduction was observed in all evaluable patients; however, none has achieved complete disappearance of the disease. The haemopoietic reconstitution was significantly delayed in 3 patients. These preliminary results show the feasibility of this approach in advanced MM patients with heavily infiltrated marrow. The place of ABMT in the treatment of MM remains to be determined; the selection of patients with still responding and less advanced disease would probably produce better results.

Original languageEnglish
Pages (from-to)176-181
Number of pages6
JournalEuropean Journal of Haematology, Supplement
Volume43
Issue number51
Publication statusPublished - 1989

Fingerprint

Immunotoxins
Autologous Transplantation
Multiple Myeloma
Bone Marrow Transplantation
Bone Marrow
Ribosome Inactivating Proteins
B-Lymphoid Precursor Cells
Chemoradiotherapy
Plasma Cells
Bone Marrow Cells
Patient Selection
Monoclonal Antibodies
Infection
Neoplasms

ASJC Scopus subject areas

  • Hematology

Cite this

Gobbi, M., Cavo, M., Tazzari, P. L., Dinota, A., Tassi, C., Bontadin i, A., ... Tura, S. (1989). Autologous bone marrow transplantation with immunotoxin-purged marrow for advanced multiple myeloma. European Journal of Haematology, Supplement, 43(51), 176-181.

Autologous bone marrow transplantation with immunotoxin-purged marrow for advanced multiple myeloma. / Gobbi, M.; Cavo, M.; Tazzari, P. L.; Dinota, A.; Tassi, C.; Bontadin i, A.; Albertazzi, L.; Miggiano, C.; Rizzi, S.; Rosti, G.; Bolognesi, A.; Stirpe, F.; Tura, S.

In: European Journal of Haematology, Supplement, Vol. 43, No. 51, 1989, p. 176-181.

Research output: Contribution to journalArticle

Gobbi, M, Cavo, M, Tazzari, PL, Dinota, A, Tassi, C, Bontadin i, A, Albertazzi, L, Miggiano, C, Rizzi, S, Rosti, G, Bolognesi, A, Stirpe, F & Tura, S 1989, 'Autologous bone marrow transplantation with immunotoxin-purged marrow for advanced multiple myeloma', European Journal of Haematology, Supplement, vol. 43, no. 51, pp. 176-181.
Gobbi, M. ; Cavo, M. ; Tazzari, P. L. ; Dinota, A. ; Tassi, C. ; Bontadin i, A. ; Albertazzi, L. ; Miggiano, C. ; Rizzi, S. ; Rosti, G. ; Bolognesi, A. ; Stirpe, F. ; Tura, S. / Autologous bone marrow transplantation with immunotoxin-purged marrow for advanced multiple myeloma. In: European Journal of Haematology, Supplement. 1989 ; Vol. 43, No. 51. pp. 176-181.
@article{3f314f7908b14682a267083c5df5b657,
title = "Autologous bone marrow transplantation with immunotoxin-purged marrow for advanced multiple myeloma",
abstract = "A system to purge the bone marrow of myeloma cells has been developed in our laboratories with the aim of treating with myeloablative radiochemotherapy patients suffering from advanced multiple myeloma. This system is based on the ex vivo incubation of the marrow with an immunotoxin composed of the 8A monoclonal antibody - that recognizes plasma cells and B-cell precursors - and the ribosome-inactivating protein momordin. 8 patients have so far been treated. 4 are surviving from 4 to 18 months after ABMT, whereas 4 died after 1 to 6 months, 2 from infections, 1 from relapsing disease and 1 from veno-occlusive disease. A marked tumour reduction was observed in all evaluable patients; however, none has achieved complete disappearance of the disease. The haemopoietic reconstitution was significantly delayed in 3 patients. These preliminary results show the feasibility of this approach in advanced MM patients with heavily infiltrated marrow. The place of ABMT in the treatment of MM remains to be determined; the selection of patients with still responding and less advanced disease would probably produce better results.",
author = "M. Gobbi and M. Cavo and Tazzari, {P. L.} and A. Dinota and C. Tassi and {Bontadin i}, A. and L. Albertazzi and C. Miggiano and S. Rizzi and G. Rosti and A. Bolognesi and F. Stirpe and S. Tura",
year = "1989",
language = "English",
volume = "43",
pages = "176--181",
journal = "Scandinavian journal of haematology. Supplementum",
issn = "0902-4506",
publisher = "Wiley-Blackwell",
number = "51",

}

TY - JOUR

T1 - Autologous bone marrow transplantation with immunotoxin-purged marrow for advanced multiple myeloma

AU - Gobbi, M.

AU - Cavo, M.

AU - Tazzari, P. L.

AU - Dinota, A.

AU - Tassi, C.

AU - Bontadin i, A.

AU - Albertazzi, L.

AU - Miggiano, C.

AU - Rizzi, S.

AU - Rosti, G.

AU - Bolognesi, A.

AU - Stirpe, F.

AU - Tura, S.

PY - 1989

Y1 - 1989

N2 - A system to purge the bone marrow of myeloma cells has been developed in our laboratories with the aim of treating with myeloablative radiochemotherapy patients suffering from advanced multiple myeloma. This system is based on the ex vivo incubation of the marrow with an immunotoxin composed of the 8A monoclonal antibody - that recognizes plasma cells and B-cell precursors - and the ribosome-inactivating protein momordin. 8 patients have so far been treated. 4 are surviving from 4 to 18 months after ABMT, whereas 4 died after 1 to 6 months, 2 from infections, 1 from relapsing disease and 1 from veno-occlusive disease. A marked tumour reduction was observed in all evaluable patients; however, none has achieved complete disappearance of the disease. The haemopoietic reconstitution was significantly delayed in 3 patients. These preliminary results show the feasibility of this approach in advanced MM patients with heavily infiltrated marrow. The place of ABMT in the treatment of MM remains to be determined; the selection of patients with still responding and less advanced disease would probably produce better results.

AB - A system to purge the bone marrow of myeloma cells has been developed in our laboratories with the aim of treating with myeloablative radiochemotherapy patients suffering from advanced multiple myeloma. This system is based on the ex vivo incubation of the marrow with an immunotoxin composed of the 8A monoclonal antibody - that recognizes plasma cells and B-cell precursors - and the ribosome-inactivating protein momordin. 8 patients have so far been treated. 4 are surviving from 4 to 18 months after ABMT, whereas 4 died after 1 to 6 months, 2 from infections, 1 from relapsing disease and 1 from veno-occlusive disease. A marked tumour reduction was observed in all evaluable patients; however, none has achieved complete disappearance of the disease. The haemopoietic reconstitution was significantly delayed in 3 patients. These preliminary results show the feasibility of this approach in advanced MM patients with heavily infiltrated marrow. The place of ABMT in the treatment of MM remains to be determined; the selection of patients with still responding and less advanced disease would probably produce better results.

UR - http://www.scopus.com/inward/record.url?scp=0024835630&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024835630&partnerID=8YFLogxK

M3 - Article

VL - 43

SP - 176

EP - 181

JO - Scandinavian journal of haematology. Supplementum

JF - Scandinavian journal of haematology. Supplementum

SN - 0902-4506

IS - 51

ER -